Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib plus Sorafenib in Advanced Cancer
NCT00785226Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of refametinib in solid tumor (advanced stage), sponsored by Bayer. Primary endpoint: Safety and tolerability of escalating continuous oral dosing of RDEA119 in combination with sorafenib at 28 days. Started Nov 2008; status: completed.
02
Drugs
refametinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT00785226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785226.